| scholarly article | Q13442814 |
| P2093 | author name string | Kanwal Tariq | |
| Kulsoom Ghias | |||
| P2860 | cites work | MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability | Q22010995 |
| Mutations of two PMS homologues in hereditary nonpolyposis colon cancer | Q24318484 | ||
| Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability | Q24319995 | ||
| MicroRNAs: target recognition and regulatory functions | Q24609584 | ||
| MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2) | Q24630209 | ||
| MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer | Q24643430 | ||
| MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression | Q24643470 | ||
| The colorectal cancer risk at 18q21 is caused by a novel variant altering SMAD7 expression | Q24647961 | ||
| CpG island methylator phenotype in colorectal cancer | Q24672170 | ||
| KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. | Q27851422 | ||
| Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer | Q27851456 | ||
| Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers | Q27851674 | ||
| Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis | Q27853129 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| Lessons from hereditary colorectal cancer | Q28131788 | ||
| Overexpression and mistargeting of centromere protein-A in human primary colorectal cancer | Q28184405 | ||
| Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human | Q28189663 | ||
| let-7 microRNA functions as a potential growth suppressor in human colon cancer cells | Q28237683 | ||
| DNA mismatch repair | Q28256190 | ||
| Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas | Q28269089 | ||
| Cancer genes and the pathways they control | Q28275089 | ||
| Mutant KRAS in aberrant crypt foci (ACF): initiation of colorectal cancer? | Q28276612 | ||
| SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer | Q28278952 | ||
| Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features | Q28284149 | ||
| A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer | Q28289377 | ||
| Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment | Q28294448 | ||
| The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer | Q28297155 | ||
| Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer | Q28305293 | ||
| Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor | Q28592189 | ||
| CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer | Q29614277 | ||
| Evolution and functions of long noncoding RNAs | Q29614331 | ||
| Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma | Q29615026 | ||
| Hypomethylation distinguishes genes of some human cancers from their normal counterparts | Q29619217 | ||
| Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas | Q29620630 | ||
| Up-regulation of the mitotic checkpoint component Mad1 causes chromosomal instability and resistance to microtubule poisons | Q30524222 | ||
| Increased microtubule assembly rates influence chromosomal instability in colorectal cancer cells | Q30637438 | ||
| The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer. | Q31049554 | ||
| Reconstitution of 5'-directed human mismatch repair in a purified system | Q33222844 | ||
| Mechanisms of inactivation of MLH1 in hereditary nonpolyposis colorectal carcinoma: a novel approach | Q33270665 | ||
| Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus | Q33571385 | ||
| Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer | Q33586020 | ||
| SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway | Q33933528 | ||
| Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors | Q33942280 | ||
| Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. | Q33956668 | ||
| Clinical relevance of microsatellite instability in colorectal cancer | Q33990921 | ||
| miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase | Q34013539 | ||
| PTEN-deficient tumors depend on AKT2 for maintenance and survival | Q34016861 | ||
| The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas | Q34020549 | ||
| Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer. | Q34035601 | ||
| Long non-coding RNA MALAT1 promotes tumour growth and metastasis in colorectal cancer through binding to SFPQ and releasing oncogene PTBP2 from SFPQ/PTBP2 complex | Q34051999 | ||
| High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease | Q36051517 | ||
| Epigenetics and colorectal cancer | Q36081553 | ||
| Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer | Q36086848 | ||
| Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. | Q36276940 | ||
| The hallmarks of cancer: a long non-coding RNA point of view. | Q36391951 | ||
| Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells. | Q36577379 | ||
| Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy | Q36610301 | ||
| Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. | Q36629423 | ||
| A common genetic risk factor for colorectal and prostate cancer | Q36667989 | ||
| Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon | Q36697241 | ||
| Long non-coding RNA in cancer | Q36790436 | ||
| Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. | Q36852678 | ||
| MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers | Q36906199 | ||
| Identification of novel variants in colorectal cancer families by high-throughput exome sequencing | Q36991821 | ||
| Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening | Q37066133 | ||
| Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon: classification, molecular genetics, natural history, and clinical management | Q37099611 | ||
| CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer | Q37138668 | ||
| MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial | Q37185814 | ||
| Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis. | Q37209240 | ||
| MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis | Q37209436 | ||
| Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/β-catenin signal pathway. | Q37297589 | ||
| The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment | Q37366259 | ||
| Colorectal carcinomas with CpG island methylator phenotype 1 frequently contain mutations in chromatin regulators. | Q37570042 | ||
| Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer | Q37578728 | ||
| The expanding universe of p53 targets | Q37602507 | ||
| Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis | Q37650965 | ||
| IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis | Q37679965 | ||
| Inversion of exons 1-7 of the MSH2 gene is a frequent cause of unexplained Lynch syndrome in one local population | Q37699062 | ||
| MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer | Q37715770 | ||
| EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients | Q38069531 | ||
| PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types | Q38084846 | ||
| Role of microRNAs in the immune system, inflammation and cancer | Q38110271 | ||
| Small molecule with big role: MicroRNAs in cancer metastatic microenvironments | Q38159262 | ||
| Mismatch repair pathway: molecules, functions, and role in colorectal carcinogenesis. | Q38194897 | ||
| The dual nature of mismatch repair as antimutator and mutator: for better or for worse | Q38246275 | ||
| MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer. | Q38247982 | ||
| ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer | Q38532510 | ||
| Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP. | Q38934179 | ||
| Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g. | Q39112884 | ||
| Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression | Q39249155 | ||
| Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells. | Q39387335 | ||
| Colon cancer associated transcript-1: a novel RNA expressed in malignant and pre-malignant human tissues. | Q39547104 | ||
| MALAT-1: A long non-coding RNA and its important 3' end functional motif in colorectal cancer metastasis | Q39556569 | ||
| Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells | Q39633529 | ||
| Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells | Q39634084 | ||
| miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. | Q39677748 | ||
| Epigenetic and genetic alterations in Netrin-1 receptors UNC5C and DCC in human colon cancer. | Q34069798 | ||
| Interleukin 6 downregulates p53 expression and activity by stimulating ribosome biogenesis: a new pathway connecting inflammation to cancer | Q34116561 | ||
| miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions | Q34237504 | ||
| A CpG island methylator phenotype of colorectal cancer that is contiguous with conventional adenomas, but not serrated polyps | Q34293192 | ||
| Centromere protein H is up-regulated in primary human colorectal cancer and its overexpression induces aneuploidy | Q34423165 | ||
| The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer | Q34441849 | ||
| Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer | Q34461429 | ||
| Mechanisms underlying losses of heterozygosity in human colorectal cancers | Q34485665 | ||
| Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. | Q34553646 | ||
| Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer | Q34563305 | ||
| The chromosomal instability pathway in colon cancer | Q34570062 | ||
| Microsatellite instability in colorectal cancer-the stable evidence | Q34616565 | ||
| KRAS mutation testing in metastatic colorectal cancer | Q34643960 | ||
| MALAT1 promotes colorectal cancer cell proliferation/migration/invasion via PRKA kinase anchor protein 9. | Q34718248 | ||
| Association between molecular subtypes of colorectal cancer and patient survival | Q34759064 | ||
| TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells | Q34926012 | ||
| American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy | Q34935716 | ||
| Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations | Q34959257 | ||
| Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas | Q35004950 | ||
| MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. | Q35008686 | ||
| Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. | Q35013762 | ||
| Over-expression of COX-2 mRNA in colorectal cancer | Q35079511 | ||
| Genetic variability in key genes in prostaglandin E2 pathway (COX-2, HPGD, ABCC4 and SLCO2A1) and their involvement in colorectal cancer development | Q35138248 | ||
| P53 mutations occur more commonly than KRAS mutations in colorectal adenoma | Q35173907 | ||
| Aberrations of BUBR1 and TP53 gene mutually associated with chromosomal instability in human colorectal cancer. | Q35293923 | ||
| Boosting Wnt activity during colorectal cancer progression through selective hypermethylation of Wnt signaling antagonists | Q35459134 | ||
| Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages | Q35579056 | ||
| The 5-methylcytosine content of DNA from human tumors | Q35689206 | ||
| The relationship between hypomethylation and CpG island methylation in colorectal neoplasia | Q35749254 | ||
| Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer | Q35762264 | ||
| Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers | Q35810106 | ||
| Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample | Q35855515 | ||
| Mutations associated with HNPCC predisposition -- Update of ICG-HNPCC/INSiGHT mutation database | Q35940640 | ||
| Epigenetic regulation of microRNA expression in colorectal cancer | Q39838959 | ||
| The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras | Q39860132 | ||
| Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer | Q40847447 | ||
| BRAF mutation-specific promoter methylation of FOX genes in colorectal cancer | Q41056167 | ||
| Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas | Q41603218 | ||
| 5-Methylcytosine content of nuclear DNA during chemical hepatocarcinogenesis and in carcinomas which result | Q41668069 | ||
| miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer | Q42051478 | ||
| Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer | Q42175718 | ||
| Telomere shortening of epithelial cells characterises the adenoma-carcinoma transition of human colorectal cancer | Q43005462 | ||
| Extensive telomere erosion in the initiation of colorectal adenomas and its association with chromosomal instability | Q43522906 | ||
| Recurrence and variability of germline EPCAM deletions in Lynch syndrome. | Q44080353 | ||
| Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro | Q44206354 | ||
| Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors | Q44383505 | ||
| A novel classification of colorectal tumors based on microsatellite instability, the CpG island methylator phenotype and chromosomal instability: implications for prognosis. | Q44490075 | ||
| Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability | Q44714286 | ||
| Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene | Q45345254 | ||
| Polymorphisms of the pri-miR-34b/c promoter and TP53 codon 72 are associated with risk of colorectal cancer | Q45740901 | ||
| MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies | Q45790076 | ||
| Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer. | Q46275729 | ||
| Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer | Q46578998 | ||
| Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer | Q46676671 | ||
| Three classes of genes mutated in colorectal cancers with chromosomal instability | Q47652214 | ||
| Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability | Q47704165 | ||
| Germline epimutation of MLH1 in individuals with multiple cancers | Q47817335 | ||
| Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer | Q48084125 | ||
| Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers | Q51856604 | ||
| Role of miR-143 targeting KRAS in colorectal tumorigenesis | Q52591361 | ||
| Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome | Q53085005 | ||
| Downregulation of anti-oncomirs miR-143/145 cluster occurs before APC gene aberration in the development of colorectal tumors | Q53258270 | ||
| Loss of imprinting of IGF2 correlates with hypomethylation of the H19 differentially methylated region in the tumor tissue of colorectal cancer patients | Q53272678 | ||
| Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications | Q54389429 | ||
| Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors. | Q54632294 | ||
| CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels. | Q54797906 | ||
| Variable 5-methylcytosine levels in human tumor cell lines and fresh pediatric tumor explants. | Q55489110 | ||
| Hypomethylation of L1 retrotransposons in colorectal cancer and adjacent normal tissue | Q56589628 | ||
| Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer | Q57240062 | ||
| Large genomic rearrangements and germline epimutations in Lynch syndrome | Q57671334 | ||
| Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro | Q62061836 | ||
| Hypomethylation of DNA from benign and malignant human colon neoplasms | Q69381419 | ||
| Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers | Q71167724 | ||
| Allelic loss of chromosome 18q and prognosis in colorectal cancer | Q72024722 | ||
| Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome | Q72657543 | ||
| Hereditary colorectal cancer | Q73088287 | ||
| Infrequent somatic mutation of the adenomatous polyposis coli gene in aberrant crypt foci of human colon tissue | Q77221792 | ||
| Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability | Q77534962 | ||
| Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2 | Q78532732 | ||
| A new variant database for mismatch repair genes associated with Lynch syndrome | Q79909235 | ||
| Oncogenic mutations of PIK3CA in human cancers | Q80826963 | ||
| Genetic and epigenetic factors in regulation of microRNA in colorectal cancers | Q84990760 | ||
| MicroRNAs in cancer | Q86065522 | ||
| β-Catenin signaling dosage dictates tissue-specific tumor predisposition in Apc-driven cancer | Q87418047 | ||
| P433 | issue | 1 | |
| P921 | main subject | colorectal cancer | Q188874 |
| carcinogenesis | Q1637543 | ||
| colorectal carcinoma | Q25493920 | ||
| P304 | page(s) | 120-135 | |
| P577 | publication date | 2016-03-01 | |
| P1433 | published in | Cancer Biology & Medicine | Q26841841 |
| P1476 | title | Colorectal cancer carcinogenesis: a review of mechanisms | |
| P478 | volume | 13 |
| Q57825805 | Biological Activities of Lactose-Derived Prebiotics and Symbiotic with Probiotics on Gastrointestinal System |
| Q60046390 | Biomarkers in colorectal cancer: Current clinical utility and future perspectives |
| Q58083191 | CBX8 and CD96 Are Important Prognostic Biomarkers of Colorectal Cancer |
| Q33720978 | Colorectal Cancer: From the Genetic Model to Posttranscriptional Regulation by Noncoding RNAs |
| Q55427306 | Comprehensive identification of long noncoding RNAs in colorectal cancer. |
| Q61451202 | Correlation analysis of IL-4, IL-10 and APN levels with postoperative infection of colorectal cancer |
| Q43492228 | Current and future biomarkers in colorectal cancer |
| Q64232966 | Dark-colored maple syrup treatment induces S-phase cell cycle arrest via reduced proliferating cell nuclear antigen expression in colorectal cancer cells |
| Q37620355 | Diagnostic Accuracy of Methylated SEPT9 for Blood-based Colorectal Cancer Detection: A Systematic Review and Meta-Analysis |
| Q57177421 | Diagnostic Value of Methylated for Colorectal Cancer Detection |
| Q49553034 | Early and Partial Reduction in CD4+Foxp3+ Regulatory T Cells during Colitis-Associated Colon Cancer Induces CD4+ and CD8+ T Cell Activation Inhibiting Tumorigenesis. |
| Q58701476 | Endoplasmic reticulum retention motif fused to recombinant anti-cancer monoclonal antibody (mAb) CO17-1A affects mAb expression and plant stress response |
| Q92446005 | Energy Restriction and Colorectal Cancer: A Call for Additional Research |
| Q90357653 | From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers |
| Q92281986 | Germline Pathogenic Variants in Homologous Recombination and DNA Repair Genes in an Asian Cohort of Young-Onset Colorectal Cancer |
| Q90002679 | Identification of new binding proteins of focal adhesion kinase using immunoprecipitation and mass spectrometry |
| Q37619856 | Important molecular genetic markers of colorectal cancer. |
| Q55121561 | Innovative Disease Model: Zebrafish as an In Vivo Platform for Intestinal Disorder and Tumors. |
| Q57784960 | Ixazomib promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer cells |
| Q64055535 | KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib |
| Q49843545 | MAD2L2 inhibits colorectal cancer growth by promoting NCOA3 ubiquitination and degradation |
| Q90749821 | Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer |
| Q92715583 | Mutation Spectrum of Cancer-Associated Genes in Patients With Early Onset of Colorectal Cancer |
| Q54935837 | PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments. |
| Q58088154 | Positive correlation between interleukin-1 receptor antagonist gene 86bp VNTR polymorphism and colorectal cancer susceptibility: a case-control study |
| Q90636259 | Potential Influences of RNF6 on Prognosis and Metastasis of Colorectal Cancer: A Clinical Analysis |
| Q49677613 | Promoter methylation of Wnt/β-Catenin signal inhibitor TMEM88 is associated with unfavorable prognosis of non-small cell lung cancer |
| Q56979087 | Protein Kinase C Inhibitors Selectively Modulate Dynamics of Cell Adhesion Molecules and Cell Death in Human Colon Cancer Cells |
| Q90701782 | SLC6A14, a Na+/Cl--coupled amino acid transporter, functions as a tumor promoter in colon and is a target for Wnt signaling |
| Q61809837 | Self-antigen MASH2 combined with the AS15 immunostimulant induces tumor protection in colorectal cancer mouse models |
| Q93022673 | Somatic deletion of KDM1A/LSD1 gene is associated to advanced colorectal cancer stages |
| Q64890386 | Squalene Epoxidase Inversely Correlates E-Cadherin Expression and Prolongs Overall Survival in Colorectal Cancer Patients: The Impact on Prognosis and Correlation to Clinicopathologic Features. |
| Q92437819 | Synthesis and evaluation of novel naphthol diazenyl scaffold based Schiff bases as potential antimicrobial and cytotoxic agents against human colorectal carcinoma cell line (HT-29) |
| Q90092804 | The CARM1-p300-c-Myc-Max (CPCM) transcriptional complex regulates the expression of CUL4A/4B and affects the stability of CRL4 E3 ligases in colorectal cancer |
| Q38618938 | The cardiac glycoside convallatoxin inhibits the growth of colorectal cancer cells in a p53-independent manner. |
| Q64078859 | Upregulation of SLC2A3 gene and prognosis in colorectal carcinoma: analysis of TCGA data |
Search more.